85 related articles for article (PubMed ID: 8372614)
1. ["Critical point" as a risk factor of central nervous system hemorrhagic complications in patients with blastic phase of chronic myelogenous leukemia].
Nowacki P; Zdziarska B
Acta Haematol Pol; 1993; 24(2):147-51. PubMed ID: 8372614
[TBL] [Abstract][Full Text] [Related]
2. Hemiballismus in patient with blastic phase of chronic myelogenous leukemia.
Nowacki P; Zdziarska B; Zyluk B; Jankowska-Kurek I
Neuropatol Pol; 1993; 31(3-4):143-8. PubMed ID: 7792011
[TBL] [Abstract][Full Text] [Related]
3. Cardiac tamponade in the blastic crisis of chronic myelogenous leukemia.
Yamauchi K; Arimori S; Nagao T
Tokai J Exp Clin Med; 1992 Jul; 17(2):89-93. PubMed ID: 1440659
[TBL] [Abstract][Full Text] [Related]
4. [Causes of death in chronic myeloid leukemia. Analysis of 109 patients].
Cervantes F; Sanz C; Bosch F; Rozman C
Sangre (Barc); 1991 Jun; 36(3):183-6. PubMed ID: 1948535
[TBL] [Abstract][Full Text] [Related]
5. Leukemic cells growth fraction in the central nervous system in blastic phase of chronic myelogenous leukemia.
Zdziarska B; Nowacki P
Acta Haematol Pol; 1996; 27(1):43-8. PubMed ID: 8629442
[TBL] [Abstract][Full Text] [Related]
6. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
7. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Kantarjian H; O'Brien S; Cortes J; Giles F; Thomas D; Kornblau S; Shan J; Beth Rios M; Keating M; Freireich E; Talpaz M
Cancer; 2003 Jul; 98(1):81-5. PubMed ID: 12833459
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
9. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
10. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
11. Management of the cardiac tamponade as a first clinical manifestation of extramedullary blast crisis in chronic myelogenous leukemia.
Macia J
Eur J Haematol; 1995 Jul; 55(1):65-6. PubMed ID: 7615054
[No Abstract] [Full Text] [Related]
12. Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case.
Yu HH; Lu MY; Lin DT; Lin KH; Tang JL; Jou ST
Acta Paediatr Taiwan; 2006; 47(3):150-4. PubMed ID: 17078470
[TBL] [Abstract][Full Text] [Related]
13. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
[TBL] [Abstract][Full Text] [Related]
14. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
17. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
18. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
19. [Undifferentiated blastic cell crisis of chronic myelogenous leukemia with myeloblastic tumor in the skin].
Kawakami K; Kiyosaki M; Amaya H; Nakamaki T; Hino K; Tomoyasu S
Rinsho Ketsueki; 2000 Apr; 41(4):334-40. PubMed ID: 10846465
[TBL] [Abstract][Full Text] [Related]
20. Co-existence of thrombocytopenia and hyperleukocytosis ('critical period') as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias.
Nowacki P; Zdziarska B; Fryze C; Urasiński I
Haematologia (Budap); 2002; 31(4):347-55. PubMed ID: 12038519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
